Asunto(s)
Vacunas contra la COVID-19 , Industria Farmacéutica/historia , Investigadores/historia , Investigación/historia , Vacunas Sintéticas/historia , Animales , Ensayos Clínicos como Asunto , Industria Farmacéutica/economía , Terapia Genética/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Liposomas , Ratones , Nanopartículas/química , Neoplasias/genética , Neoplasias/inmunología , Neoplasias/terapia , Premio Nobel , Patentes como Asunto/historia , Seudouridina/metabolismo , ARN/biosíntesis , ARN/genética , Estabilidad del ARN , Conejos , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/inmunología , Receptores Toll-Like/inmunología , Vacunas de ADN/historia , Vacunas Sintéticas/efectos adversos , Vacunas Sintéticas/uso terapéutico , Vacunas de ARNmAsunto(s)
Vacunas contra la Malaria/historia , Vacunas Sintéticas/historia , Niño , Preescolar , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Lactante , Malaria/historia , Malaria/prevención & control , Vacunas contra la Malaria/uso terapéutico , Malaria Falciparum/prevención & control , Mozambique , Plasmodium falciparum , Ensayos Clínicos Controlados Aleatorios como Asunto/historia , Vacunas Sintéticas/uso terapéuticoRESUMEN
Although viruses and bacteria have been known as agents of diseases since 1546, 250 years went by until the first vaccines against these pathogens were developed (1796 and 1800s). In contrast, Malaria, which is a protozoan-neglected disease, has been known since the 5th century BCE and, despite 2,500 years having passed since then, no human vaccine has yet been licensed for Malaria. Additionally, no modern human vaccine is currently licensed against Visceral or Cutaneous leishmaniasis. Vaccination against Malaria evolved from the inoculation of irradiated sporozoites through the bite of Anopheles mosquitoes in 1930's, which failed to give protection, to the use of controlled human Malaria infection (CHMI) provoked by live sporozoites of Plasmodium falciparum and curtailed with specific chemotherapy since 1940's. Although the use of CHMI for vaccination was relatively efficacious, it has some ethical limitations and was substituted by the use of injected recombinant vaccines expressing the main antigens of the parasite cycle, starting in 1980. Pre-erythrocytic (PEV), Blood stage (BSV), transmission-blocking (TBV), antitoxic (AT), and pregnancy-associated Malaria vaccines are under development. Currently, the RTS,S-PEV vaccine, based on the circumsporozoite protein, is the only one that has arrived at the Phase III trial stage. The "R" stands for the central repeat region of Plasmodium (P.) falciparum circumsporozoite protein (CSP); the "T" for the T-cell epitopes of the CSP; and the "S" for hepatitis B surface antigen (HBsAg). In Africa, this latter vaccine achieved only 36.7% vaccine efficacy (VE) in 5-7 years old children and was associated with an increase in clinical cases in one assay. Therefore, in spite of 35 years of research, there is no currently licensed vaccine against Malaria. In contrast, more progress has been achieved regarding prevention of leishmaniasis by vaccine, which also started with the use of live vaccines. For ethical reasons, these were substituted by second-generation subunit or recombinant DNA and protein vaccines. Currently, there is one live vaccine for humans licensed in Uzbekistan, and four licensed veterinary vaccines against visceral leishmaniasis: Leishmune® (76-80% VE) and CaniLeish® (68.4% VE), which give protection against strong endpoints (severe disease and deaths under natural conditions), and, under less severe endpoints (parasitologically and PCR-positive cases), Leishtec® developed 71.4% VE in a low infective pressure area but only 35.7% VE and transient protection in a high infective pressure area, while Letifend® promoted 72% VE. A human recombinant vaccine based on the Nucleoside hydrolase NH36 of Leishmania (L.) donovani, the main antigen of the Leishmune® vaccine, and the sterol 24-c-methyltransferase (SMT) from L. (L.) infantum has reached the Phase I clinical trial phase but has not yet been licensed against the disease. This review describes the history of vaccine development and is focused on licensed formulations that have been used in preventive medicine. Special attention has been given to the delay in the development and licensing of human vaccines against Protozoan infections, which show high incidence worldwide and still remain severe threats to Public Health.
Asunto(s)
Leishmania donovani/inmunología , Vacunas contra la Leishmaniasis/historia , Leishmaniasis Visceral/prevención & control , Concesión de Licencias/historia , Vacunas contra la Malaria/historia , Malaria Falciparum/prevención & control , Vacunación Masiva/historia , Plasmodium falciparum/inmunología , Adulto , Animales , Niño , Preescolar , Femenino , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas contra la Leishmaniasis/inmunología , Leishmaniasis Visceral/parasitología , Leishmaniasis Visceral/veterinaria , Vacunas contra la Malaria/inmunología , Malaria Falciparum/parasitología , Vacunación Masiva/métodos , Embarazo , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Vivas no Atenuadas/historia , Vacunas Vivas no Atenuadas/inmunología , Vacunas Sintéticas/historia , Vacunas Sintéticas/inmunologíaAsunto(s)
Química Orgánica/historia , Oligonucleótidos/síntesis química , Historia del Siglo XX , Historia del Siglo XXI , Países Bajos , Oligonucleótidos/química , Oligonucleótidos/genética , Oligonucleótidos/historia , Oligosacáridos/síntesis química , Oligosacáridos/historia , Estados Unidos , Vacunas Sintéticas/historiaRESUMEN
After Edward Jenner established human vaccination over 200 years ago, attenuated poxviruses became key players to contain the deadliest virus of its own family: Variola virus (VARV), the causative agent of smallpox. Cowpox virus (CPXV) and horsepox virus (HSPV) were extensively used to this end, passaged in cattle and humans until the appearance of vaccinia virus (VACV), which was used in the final campaigns aimed to eradicate the disease, an endeavor that was accomplished by the World Health Organization (WHO) in 1980. Ever since, naturally evolved strains used for vaccination were introduced into research laboratories where VACV and other poxviruses with improved safety profiles were generated. Recombinant DNA technology along with the DNA genome features of this virus family allowed the generation of vaccines against heterologous diseases, and the specific insertion and deletion of poxvirus genes generated an even broader spectrum of modified viruses with new properties that increase their immunogenicity and safety profile as vaccine vectors. In this review, we highlight the evolution of poxvirus vaccines, from first generation to the current status, pointing out how different vaccines have emerged and approaches that are being followed up in the development of more rational vaccines against a wide range of diseases.
Asunto(s)
Vacuna contra Viruela/historia , Vacuna contra Viruela/aislamiento & purificación , Viruela/prevención & control , Animales , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Poxviridae/inmunología , Poxviridae/aislamiento & purificación , Vacuna contra Viruela/inmunología , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/aislamiento & purificación , Vacunas Sintéticas/historia , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/aislamiento & purificaciónRESUMEN
Vaccination against influenza represents our most effective form of prevention. Historical approaches toward vaccine creation and production have yielded highly effective vaccines that are safe and immunogenic. Despite their effectiveness, these historical approaches do not allow for the incorporation of changes into the vaccine in a timely manner. In 2013, a recombinant protein-based vaccine that induces immunity toward the influenza virus hemagglutinin was approved for use in the USA. This vaccine represents the first approved vaccine formulation that does not require an influenza virus intermediate for production. This review presents a brief history of influenza vaccines, with insight into the potential future application of vaccines generated using recombinant technology.
Asunto(s)
Descubrimiento de Drogas/tendencias , Vacunas contra la Influenza/inmunología , Vacunas contra la Influenza/aislamiento & purificación , Tecnología Farmacéutica/tendencias , Descubrimiento de Drogas/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Vacunas contra la Influenza/historia , Gripe Humana/prevención & control , Tecnología Farmacéutica/historia , Estados Unidos , Vacunas Atenuadas/historia , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/aislamiento & purificación , Vacunas de Productos Inactivados/historia , Vacunas de Productos Inactivados/inmunología , Vacunas de Productos Inactivados/aislamiento & purificación , Vacunas de Subunidad/historia , Vacunas de Subunidad/inmunología , Vacunas de Subunidad/aislamiento & purificación , Vacunas Sintéticas/historia , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/aislamiento & purificaciónRESUMEN
Live vaccines against fowlpox virus, which causes moderate pathology in poultry and is the type species of the Avipoxvirus genus, were developed in the 1920s. Development of recombinant fowlpox virus vector vaccines began in the 1980s, for use not only in poultry, but also in mammals including humans. In common with other avipoxviruses, such as canarypox virus, fowlpox virus enters mammalian cells and expresses proteins, but replicates abortively. The use of fowlpox virus as a safe vehicle for expression of foreign antigens and host immunomodulators, is being evaluated in numerous clinical trials of vaccines against cancer, malaria, tuberculosis and AIDS, notably in heterologous prime-boost regimens. In this article, technical approaches to, and issues surrounding, the use of fowlpox virus as a recombinant vaccine vector in poultry and mammals are reviewed.
Asunto(s)
Antígenos de Neoplasias/inmunología , Vacunas contra el Cáncer/administración & dosificación , Sistemas de Liberación de Medicamentos , Virus de la Viruela de las Aves de Corral/inmunología , Melanoma/inmunología , Aves de Corral/inmunología , Vacunación/veterinaria , Vacunas Sintéticas/administración & dosificación , Vacunas Virales/administración & dosificación , Animales , Antígenos de Neoplasias/genética , Vacunas contra el Cáncer/uso terapéutico , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Virus de la Viruela de las Aves de Corral/genética , Vectores Genéticos , Historia del Siglo XX , Humanos , Mardivirus/genética , Mardivirus/inmunología , Enfermedad de Marek/prevención & control , Vacunas contra la Enfermedad de Marek/administración & dosificación , Melanoma/terapia , Vacunas Sintéticas/historia , Vacunas Sintéticas/uso terapéutico , Vacunas Virales/historia , Vacunas Virales/uso terapéuticoRESUMEN
Recent developments have made it possible to construct non-reverting live bacterial vaccine candidates with defined deletions of two or more genes. Such vaccines have proven safe and immunogenic in human volunteers. Since the virulent parent strains are only pathogenic to man (S. typhi, S. flexneri, and V. cholerae), they pose no threat to the environment. Besides holding promise as efficacious vaccines for protection against typhoid fever, bacillary dysentery and cholera, the attenuated strains are well suited as vectors for delivery of heterologous antigenic epitopes from micro-organisms such as Helicobacter pylori, Neisseira gonorrhoeae, rotavirus, HIV and many others. Instead of using a virulent parent bacterium as the starting organism for making a vector, attempts have recently been made to employ non-pathogenic bacteria of the normal human flora, such as Streptococcus gordonii for delivery of foreign antigens. At present, the feasibility of this approach for human beings remains to be proven.
Asunto(s)
Vacunas Bacterianas/historia , Animales , Infecciones Bacterianas/historia , Infecciones Bacterianas/prevención & control , Vacunas Bacterianas/genética , Vectores Genéticos , Historia del Siglo XIX , Historia del Siglo XX , Humanos , Mutación , Salmonella typhi/genética , Salmonella typhi/inmunología , Shigella/genética , Shigella/inmunología , Vacunas Atenuadas/historia , Vacunas Sintéticas/historia , Vibrio cholerae/inmunologíaRESUMEN
Live attenuated vaccines administered directly to the respiratory tract offer the promise of providing more effective immunity against influenza than subunit or split inactivated vaccines. Evidence has accumulated in recent years that immunological responses relevant to both the prevention of and recovery from influenza are best induced by natural infection. The ease with which the genes of influenza viruses reassort when two or more viruses infect a single cell has been exploited as a means of rapidly producing attenuated vaccines. Donor strains that have been shown by extensive testing to be fully attenuated are used to co-infect cells with contemporary epidemic strains to produce reassortants with the required degree of avirulence and the surface antigens of the epidemic strain. Reassortants prepared from cold-adapted mutants of both influenza A and B viruses have been widely shown from clinical trials in both the United States and Russia over many years to be well tolerated in both adults and children and to be highly efficacious.
Asunto(s)
Vacunas contra la Influenza , Adulto , Anciano , Animales , Niño , Historia del Siglo XX , Humanos , Virus de la Influenza A/genética , Virus de la Influenza A/inmunología , Virus de la Influenza B/genética , Virus de la Influenza B/inmunología , Vacunas contra la Influenza/efectos adversos , Vacunas contra la Influenza/genética , Vacunas contra la Influenza/historia , Especificidad de la Especie , Vacunas Atenuadas/efectos adversos , Vacunas Atenuadas/genética , Vacunas Atenuadas/historia , Vacunas de Productos Inactivados/historia , Vacunas Sintéticas/genética , Vacunas Sintéticas/historiaRESUMEN
In reviewing 50 years of personal research on influenza, I have journeyed, literally and figuratively, from an army camp epidemic in Fort Monmouth NJ in 1947 to a (literal and figurative) Valhalla, where I now conduct my research. Having entered the field as a physician, I have always sought practical applications of my work, yet in every instance, such applications have led me to seek further answers in basic research as new questions arose. I entered the area of influenza virus genetics by the back door through an interest in the effects of corticosteroid hormones on viral replication, used the genetic approach in analyzing the morphological variation of the virus and, in so doing, exploited the finding of a linkage of high-yield growth to spherical morphology. Today, all influenza vaccine viruses are high-yield genetic reassortants. Subsequent study of reassortant viruses facilitated the identification and isolation of the two major antigens of the virus in antigenic hybrids and showed their differing functions in the induction of immunity. In turn, a new approach to influenza vaccination has been discovered and is presently under clinical investigation.